Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Unique clinico-biological, genetic and prognostic features of adult early T-cell precursor acute lymphoblastic leukemia

  • Genescà, Eulàlia|||0000-0002-5657-4842
  • Morgades, Mireia|||0000-0003-0295-2534
  • Montesinos, Pau|||0000-0002-3275-5593
  • Barba, Pere|||0000-0001-7076-7969
  • Gil, Cristina
  • Guàrdia, Ramón
  • Moreno, Maria José
  • Martínez-Carballeira, Daniel|||0000-0003-4840-7822
  • García Cadenas, Irene|||0000-0002-2994-9055
  • Vives Polo, Susana|||0000-0003-2217-5285
  • Ribera Salas, Jordi|||0000-0003-4796-6470
  • González Campos, José
  • González Gil, Celia|||0000-0002-7582-1482
  • Zamora, Lurdes|||0000-0003-1713-7110
  • Ramirez, Jose Luis
  • Díaz-Beyá, Marina|||0000-0001-9624-2597
  • Mercadal, Santiago|||0000-0003-4741-7885
  • Artola, Maria Teresa
  • Cladera, Antonia
  • Tormo, Mar|||0000-0001-9622-1649
  • Bermúdez, Arancha
  • Vall-Llovera, Ferran|||0000-0002-0718-5955
  • Martínez Sánchez, Pilar|||0000-0002-7334-140X
  • Amigo, María-Luz|||0000-0002-3356-9290
  • Monsalvo, Silvia
  • Novo, Andrés
  • Cervera, Marta
  • Garcia-Guiñon, Antonio|||0000-0003-0006-4162
  • Junca, Jordi|||0000-0003-0142-772X
  • Ciudad Pizarro, Juana
  • Orfao, Alberto|||0000-0002-0007-7230
  • Ribera, Jose-Maria|||0000-0003-1042-6024
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma

  • Iacoboni, Gloria|||0000-0003-0805-9288
  • Villacampa Javierre, Guillermo|||0000-0003-4868-6585
  • Martínez Cibrián, Núria|||0000-0002-8688-1202
  • Bailén, Rebeca|||0000-0003-2838-1776
  • López Corral, Lucia|||0000-0003-1908-5596
  • Sánchez Pina, José María|||0000-0002-9181-0900
  • Guerreiro, Manuel
  • Caballero, Ana Carolina|||0000-0002-4950-5259
  • Mussetti, Alberto|||0000-0002-4088-036X
  • Sancho, Juan-Manuel|||0000-0001-7168-6538
  • Hernani, Rafael|||0000-0003-1043-8076
  • Abrisqueta, Pau|||0000-0001-9625-7422
  • Solano, Carlos|||0000-0003-3702-0817
  • Sureda, Anna|||0000-0002-1238-6970
  • Briones Meijide, Javier|||0000-0003-2750-3735
  • Martín García-Sancho, Alejandro|||0000-0001-6330-1028
  • Kwon, Mi|||0000-0002-3855-7774
  • Reguera-Ortega, Juan Luis
  • Barba, Pere|||0000-0001-7076-7969
Tisagenlecleucel (tisa-cel) is a second-generation autologous CD19-targeted chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). The approval was based on the results of phase II JULIET trial, with a best overall response rate (ORR) and complete response (CR) rate in infused patients of 52% and 40%, respectively. We report outcomes with tisa-cel in the standard-of-care (SOC) setting for R/R LBCL. Data from all patients with R/R LBCL who underwent leukapheresis from December 2018 until June 2020 with the intent to receive SOC tisa-cel were retrospectively collected at 10 Spanish institutions. Toxicities were graded according to ASTCT criteria and responses were assessed as per Lugano 2014 classification. Of 91 patients who underwent leukapheresis, 75 (82%) received tisa-cel therapy. Grade 3 or higher cytokine release syndrome and neurotoxicity occurred in 5% and 1%, respectively; non-relapse mortality was 4%. Among the infused patients, best ORR and CR were 60% and 32%, respectively, with a median duration of response of 8.9 months. With a median follow-up of 14.1 months from CAR T-cell infusion, median progression-free survival and overall survival were 3 months and 10.7 months, respectively. At 12 months, patients in CR at first disease evaluation had a PFS of 87% and OS of 93%. Patients with an elevated lactate dehydrogenase showed a shorter PFS and OS on multivariate analysis. Treatment with tisa-cel for patients with relapsed/refractory LBCL in a European SOC setting showed a manageable safety profile and durable complete responses. This article provides real-world European data on the results of relapsed/refractory large B-cell lymphoma patients treated with tisagenlecleucel.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma

  • Iacoboni, Gloria|||0000-0003-0805-9288
  • Rejeski, Kai
  • Villacampa Javierre, Guillermo|||0000-0003-4868-6585
  • van Doesum, Jaap A.|||0000-0003-0214-3219
  • Chiappella, Annalisa|||0000-0002-2977-0098
  • Bonifazi, Francesca|||0000-0003-1544-9911
  • López Corral, Lucia|||0000-0003-1908-5596
  • van Aalderen, Michiel
  • Kwon, Mi|||0000-0002-3855-7774
  • Martínez Cibrián, Núria|||0000-0002-8688-1202
  • Bramanti, Stefania
  • Reguera-Ortega, Juan Luis
  • Camacho-Arteaga, Lina|||0000-0001-9609-0394
  • Schmidt, Christian
  • Marín-Niebla, Ana|||0000-0002-7592-6815
  • Kersten, Marie José
  • Martín García-Sancho, Alejandro|||0000-0001-6330-1028
  • Zinzani, Pier Luigi|||0000-0002-2112-2651
  • Corradini, Paolo|||0000-0002-9186-1353
  • van Meerten, Tom
  • Subklewe, Marion
  • Barba, Pere|||0000-0001-7076-7969